The Global Biologics Market Analysis| Coherent Market Insights

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. BIOLOGICS MARKET ANALYSIS Biologics Market,byDrug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others)), by Therapeutic Application (Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

3. The global biologics market is estimated to be valued at US$ 255.19 Billion in 2019 and is expected to exhibit a CAGR of 7.6% over the forecast period (2019-2027). Drivers • Key players in the market have number of biopharmaceuticals products, which are in clinical trials and are expected to receive approval in the near future. Thus, robust pipeline of biopharmaceutical products is expected to significantly drive growth of global biologics market over the forecast period.  For instance, Amgen Inc. has monoclonal antibody AMG 820 and AMG 966 in phase I clinical trials, monoclonal antibody AMG 301, AMG 557, AMG 714, and Tezepelumab, in phase II clinical trials; and monoclonal antibody Aimovig (erenumab), EVENTIYTM (romosozumab), Tezepelumab, and Prolia (denosumab) in phase III clinical trials.

4. Moreover, Novartis International AG, a Switzerland-based pharmaceutical company has number of monoclonal antibodies in pipeline. The company has monoclonal antibody Xolair, Cosentyx, OMB157, RTH258, and Lucentis in phase III clinical trial; monoclonal antibodies QGE031 and BYM338 in phase II clinical trials.

5. Global Biologics Market Share (%) Analysis, By Drug Class, 2019

6. Market Restraints However, middle-to-low income economies such as India, Indonesia, Bangladesh, Mexico, Brazil, and certain European countries have inadequate availability of biologics due to high cost and lack of reimbursement for biologics. Therefore, lower availability and affordability of biologics in middle and lower income countries are expected to hamper the biologics market growth over the forecast period.  For instance, according to article ‘Affordability Issues of Biotech Drugs in Low- and Middle-Income Countries (LMICs)’ published in Drug Designing and Intellectual Properties International Journal 2019, in India alone, as many as 63 million people are forced into poverty every year, owing to very high health expenses, the majority of which, are out-of-pocket payments for medicines.

7. Regional Insights • On the basis of region, the global biologics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, North America is expected to hold a dominant position in the global biologics market over the forecast period, owing to rising number of approvals of biologics drugs by the regulatory authorities. For instance, in 2017, the U.S. FDA approved GlaxoSmithKline’s biologic Nucala for the treatment of a rare disease called eosinophilicgranulomatosis with polyangiitis (EPGA) • Asia Pacific is expected to be the fastest growing region in the global biologics market, owing to increasing prevalence of diabetes in this region. For instance, according to the International Diabetes Federation (IDF) Diabetes Atlas: 2017, number of people with diabetes aged between 20 to 79 years in South East Asia region and Western Pacific region in 2017 was 82 million and 159 million, respectively

8. Global Biologics Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

9. Competitive Section Key players operating in the global biologics market include Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.

10. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst Reference: https://www.coherentmarketinsights.com/market-insight/biologics-market-2663

11. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

12. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

13. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/